Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

  title={Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases},
  author={Alberto Lle{\'o} and Enrica Cavedo and Lucilla Parnetti and Hugo Marcel Johan Vanderstichele and Sanna Kaisa Herukka and Niels Andreasen and Roberta Ghidoni and Piotr Lewczuk and Andreas Jeromin and Bengt Winblad and Magda Tsolaki and Barbara Mroczko and Pieter Jelle Visser and Isabel Santana and Per Svenningsson and K Blennow and Dag Aarsland and Jos{\'e} Luis Molinuevo and Henrik Zetterberg and Brit Mollenhauer},
  journal={Nature Reviews Neurology},
Alzheimer disease (AD) and Parkinson disease (PD) are the most common neurodegenerative disorders. For both diseases, early intervention is thought to be essential to the success of disease-modifying treatments. Cerebrospinal fluid (CSF) can reflect some of the pathophysiological changes that occur in the brain, and the number of CSF biomarkers under investigation in neurodegenerative conditions has grown rapidly in the past 20 years. In AD, CSF biomarkers are increasingly being used in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS
36 Citations
228 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 36 extracted citations


Publications referenced by this paper.
Showing 1-10 of 228 references

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid A β 42 : a cross - validation study against amyloid PET in nondemented individuals

  • S. Palmqvist
  • JAMA Neurol .
  • 2014

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease

  • Fagan, M A.
  • Sci. Transl. Med. 6,
  • 2014

a cross-validation study against amyloid PET in non-demented individuals

  • Palmqvist, S. et al. Accuracy of brain amyloid detection in clin Aβ42
  • JAMA Neurol. 71, 1282–1289
  • 2014

Similar Papers

Loading similar papers…